| Literature DB >> 25376742 |
Jamie A Moroco1, Matthew P Baumgartner2, Heather L Rust1, Hwan Geun Choi3,4, Wooyoung Hur3,4, Nathanael S Gray3,4, Carlos J Camacho2, Thomas E Smithgall1.
Abstract
The c-Src tyrosine kinase co-operates with the focal adhesion kinase to regulate cell adhesion and motility. Focal adhesion kinase engages the regulatory SH3 and SH2 domains of c-Src, resulting in localized kinase activation that contributes to tumor cell metastasis. Using assay conditions where c-Src kinase activity required binding to a tyrosine phosphopeptide based on the focal adhesion kinase SH3-SH2 docking sequence, we screened a kinase-biased library for selective inhibitors of the Src/focal adhesion kinase peptide complex versus c-Src alone. This approach identified an aminopyrimidinyl carbamate compound, WH-4-124-2, with nanomolar inhibitory potency and fivefold selectivity for c-Src when bound to the phospho-focal adhesion kinase peptide. Molecular docking studies indicate that WH-4-124-2 may preferentially inhibit the 'DFG-out' conformation of the kinase active site. These findings suggest that interaction of c-Src with focal adhesion kinase induces a unique kinase domain conformation amenable to selective inhibition.Entities:
Keywords: SH2 domain; SH3 domain; Src kinase; cancer drug discovery; focal adhesion kinase; kinase inhibitors
Mesh:
Substances:
Year: 2014 PMID: 25376742 PMCID: PMC4444405 DOI: 10.1111/cbdd.12473
Source DB: PubMed Journal: Chem Biol Drug Des ISSN: 1747-0277 Impact factor: 2.817